Smaller portions don't automatically mean smarter nutrition.
GLP-1 medications shrink your appetite — they don't tell you what to fill the smaller plate with. SNAQ tracks protein, fibre, and muscle-loss risk so weight loss doesn't cost you strength.
GLP-1 receptor agonists (semaglutide, tirzepatide — marketed as Ozempic, Wegovy, Mounjaro, Zepbound) are diabetes and weight management medications that reduce appetite and slow gastric emptying. Common nutritional risks during GLP-1 therapy include inadequate protein intake, low fibre, and loss of lean body mass. Maintaining protein at 1.2–1.6 g/kg body weight per day is broadly recommended during active weight loss.
GLP-1 + low protein = muscle loss disguised as weight loss.
Up to 40% of weight lost on GLP-1s can be lean mass when protein intake drops alongside calories. The scale moves. Strength, metabolism, and long-term outcomes don't follow. SNAQ flags it before it shows up in a DEXA scan.
Track protein per meal — and the fibre that GLP-1 users skip first.
Every photo logs protein, fibre, and macros. SNAQ flags meals below your protein target and surfaces fibre-rich swap suggestions when intake drops.
Built on clinical evidence.
Per-meal protein scoring
SNAQ checks every meal against a protein target derived from your weight and goals — and nudges when you fall behind.
Customisable per userFibre-first swap suggestions
GLP-1 satiety drops fibre intake first. SNAQ recommends swaps — slower-digesting carbs and high-fibre proteins.
AI Nutritionist · always onOptional glucose context
Pair with Dexcom Stelo or Abbott Lingo to see how your reduced-portion meals affect glucose during dose escalation.
OTC CGMs supportedSNAQ is the only consumer nutrition app with peer-reviewed clinical evidence.
Validated in T1D patients on automated insulin delivery and built to extend to anyone wearing a sensor.
Source: eClinicalMedicine (The Lancet), 2025 · 53 T1D participants.